Vecata

Flex Funding A/S, founded in 2013 and headquartered in Hellerup, Denmark, operates a crowdfunding marketplace that connects lenders and borrowers for corporate loans. As the first crowdfunding company authorized as a payment institution by the Danish Financial Supervisory Authority, Flex Funding adheres to strict regulatory standards and capital requirements. The platform allows private individuals to lend money directly to businesses without intermediaries or hidden fees, facilitating a more efficient funding process. By enabling users to create accounts and easily apply for loans or bid as lenders, Flex Funding aims to develop the market for corporate loans, providing borrowers with flexible funding options while offering lenders the potential for high returns on their investments.

Proxeon develops solutions to solve many of the scientific and technical challenges that are faced by those working in the field of proteomics. The proteomics field draws on a wide range of knowledge, including biology, physics, engineering and informatics. Scientists at Proxeon have been actively involved in proteomics research for more than 15 years and have a proven track record in development of high quality products. With core competencies in the areas of mass spectrometry, protein analysis, hardware and software design for proteome analysis, Proxeon is capable of developing solutions, and creating a new generation of powerful proteomics tools.

Fluxome is a global supplier of natural ingredients with beneficial effects to the human health. They believe that their unique technology and their focused efforts towards developing safe and natural nutraceutical ingredients from a secure and renewable source can help make a difference for their customers.

Zoomio Holding A/S provides software solutions for digital direct marketing. It offers Zoomio Campaigner, which helps to plan, build, execute, and follow up on direct marketing campaigns, including postal campaigns, email marketing, telemarketing, SMS marketing, and inbound marketing; Wizard based Campaigner, an online marketing tool for beginners and e-marketers; Zoomio Analytics, which offers a visual tool that shows results online; Security Plus, an add on product that offers a layer of security when a user logs on to Zoomio Campaigner; and Zoomio Connector, which enables live synchronization between Zoomio Campaign data and CRM system. The company has operations in Sweden, the United Kingdom, and Russia; and a development center in Pakistan. Zoomio Holding A/S was founded in 2002 and is based in Copenhagen, Denmark with sales offices in the United States, Denmark, Germany, and Holland.

Anapa Biotech A/S develops molecular tools to enhance the performance of natural nucleic acids in PCR based assays and hybridization. Its technology offers improvement to various areas such as human and veterinary diagnostics, food and feed quality and safety, environmental surveillance, and scientific research The company also holds and grants licenses within the group of nucleic acid intercalating molecules, such as twisted intercalating nucleic acids. Anapa Biotech A/S was formerly known as QuantiBact A/S and changed its name to Anapa Biotech A/S in December 2013. The company was founded in 2002 and is based in Hørsholm, Denmark.

Fluxome is a global supplier of natural ingredients with beneficial effects to the human health. They believe that their unique technology and their focused efforts towards developing safe and natural nutraceutical ingredients from a secure and renewable source can help make a difference for their customers.

LiPlasome Pharma ApS is a biotechnology company based in Hørsholm, Denmark, specializing in drug delivery technologies for the oncology market. Founded in 2001, the company has developed a lipid-based drug delivery system that enhances the intravenous transportation of anticancer drugs and prodrugs. This system incorporates polyethylene glycol to extend the serum half-life of the medications, thus preventing their elimination by the reticuloendothelial system. LiPlasome Pharma's innovative approach includes liplasomal reformulations of widely used chemotherapeutics, such as cisplatin and oxaliplatin, aimed at providing more effective cancer treatments with reduced side effects. By focusing on improving the delivery and efficacy of anticancer therapies, LiPlasome Pharma seeks to enhance patient outcomes in cancer treatment.